Esperion outlines Q2 prescription growth, targets triple combo launch by 2027

Stock Information for Esperion Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Esperion Therapeutics Inc.

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
Esperion to Participate in Upcoming June Investor Conferences
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
HLS Therapeutics Announces Q1 2025 Financial Results
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.